Beyond Symptoms: The Search for Objective Biomarkers in Psychiatric Disorders

Key Takeaways

• Psychiatric disorders are still diagnosed largely through clinical symptoms and criteria, creating a need for objective biomarkers that can support more precise diagnosis and treatment selection.

• Biomarkers for psychiatric disorders may include genetic, molecular, neuroimaging, electroencephalography, peripheral, physiological, and digital measures, but each must be validated for a specific context of use.

• The translation of psychiatric biomarkers into clinical tools remains difficult because mental disorders are heterogeneous, symptoms overlap across diagnoses, and many signals are not yet specific or sensitive enough for individual-level decision-making.

• Biomarkers may have their first major impact in psychiatric drug development by supporting patient stratification, trial enrichment, target engagement, dose selection, and response prediction.

• The future of precision psychiatry is likely to depend on layered biomarker toolkits that combine biological, behavioral, digital, and clinical data rather than a single universal diagnostic test.

Psychiatric diagnosis depends on a clinical framework that has been essential for standardizing how mental disorders are described, recognized, and treated. The Diagnostic and Statistical Manual of Mental Disorders (DSM) remains the authoritative guide used by healthcare professionals in the United States and much of the world, providing descriptions, symptoms, and other criteria for diagnosing mental disorders. That shared language matters. It allows clinicians, researchers, payers, regulators, and patients to communicate about conditions that can present with substantial variation across individuals and care settings.

At the same time, DSM-based diagnosis reflects the historical reality of psychiatry: many disorders have been defined primarily through observable symptoms, reported experiences, functional impairment, and clinical judgment rather than objective biological tests. This does not make the framework unimportant or obsolete. It does mean that psychiatric diagnosis has often lacked the kind of laboratory, imaging, molecular, or physiological tools that help anchor diagnosis and treatment selection in other areas of medicine.

That gap has become one of the central drivers of psychiatric biomarker research. The field still lacks robust, reliable, and valid biomarkers that can support objective diagnosis and individualized treatment recommendations. For patients, this can contribute to long diagnostic journeys, trial-and-error treatment selection, and difficulty predicting who will respond to a given therapy. For drug developers, it can complicate patient selection, endpoint interpretation, and the ability to connect therapeutic mechanisms to clinically meaningful outcomes.

The search for psychiatric biomarkers is therefore not simply a search for replacements for clinical diagnosis. A more realistic goal is to add new layers of objective information to a field that still depends heavily on symptom-defined categories. Biomarkers could eventually help clarify biological subtypes, identify patients more likely to respond to specific interventions, support earlier detection, or strengthen clinical trial design. For now, however, the field must navigate a careful balance: recognizing the clinical utility of existing diagnostic systems while acknowledging that psychiatry needs more objective tools to support more precise and individualized care.

Before evaluating the promise of psychiatric biomarkers, it is important to define the term carefully. In mental health, a biomarker should not be treated as a synonym for any measurable feature of a patient’s experience, behavior, or biology. The distinction matters because psychiatric disorders can be assessed through many kinds of data, from symptom scales and patient-reported outcomes to brain imaging, blood-based assays, genetic testing, wearable sensors, and smartphone-derived behavioral patterns. Not all of these are biomarkers in the same sense, and not all are equally close to the biology of disease.

In psychiatry, biomarkers may have relevance across many points in the disease and care continuum, including pathogenesis, first clinical manifestations, diagnosis, treatment outcome, and recovery.¹ That breadth is useful, but it also creates ambiguity. A biomarker might be used to help identify risk before symptoms appear, support diagnosis after symptoms emerge, predict likely treatment response, monitor biological change during therapy, or provide evidence that a drug is engaging its intended target. Each of those uses requires a different level of evidence and a clearly defined purpose.

The range of candidate biomarkers under investigation reflects that complexity. Psychiatric biomarker research has investigated genetics, transcriptomics, proteomics, metabolomics, and epigenetics, as well as genetic, molecular, neuroimaging, and peripheral assays across multiple psychiatric disorder areas.^1,2 This broad search makes sense given the biological diversity of psychiatric illness, but it also underscores why translation has been difficult. A signal that correlates with a diagnosis in one research cohort may not be specific enough, reproducible enough, or clinically meaningful enough to guide decisions for individual patients.

The terminology becomes even more complicated with digital measurement. Digital biomarker language in psychiatry remains unsettled, and some measures described as digital biomarkers include self-report, social, behavioral, cognitive, and physiological indicators.³ These tools may be valuable, particularly for capturing real-world function, sleep, activity, speech patterns, or changes in behavior over time. But the term “biomarker” can become too broad if it includes every digital measure that appears clinically relevant.

A more disciplined approach is to reserve the biomarker label for measures connected to a plausible biological pathway or disease-relevant process. That standard does not diminish the value of behavioral or digital data; rather, it helps distinguish between clinical measures, functional measures, physiological signals, and biological markers. For psychiatric biomarkers to become useful in diagnosis, prognosis, stratification, response prediction, or pharmacodynamic assessment, they need to be more than measurable. They need to be interpretable, reproducible, linked to a defined context of use, and capable of improving a decision that clinicians, researchers, or drug developers already need to make.

The challenge in psychiatric biomarker development is not that researchers have found no biological signals associated with mental disorders. The challenge is that those signals must be translated into tools that are specific, sensitive, valid, reproducible, and clinically useful at the level of the individual patient. That is a much higher bar than identifying a group-level association in a research study.

Mental disorders are heterogeneous, and symptoms often overlap across diagnostic categories, making it difficult to establish diagnostic biomarkers with the specificity, sensitivity, and validity required for clinical use.⁴ A biological or physiological signal may be associated with depression, schizophrenia, bipolar disorder, anxiety, or posttraumatic stress disorder in a study population, but that does not mean it can reliably distinguish one condition from another in a patient sitting across from a clinician. It also may not clarify whether the signal reflects disease biology, symptom severity, medication exposure, stress, sleep disruption, comorbidity, or another contributing factor.

This problem is especially important because psychiatric diagnoses often group together patients with similar symptom patterns but potentially different underlying biology. The reverse is also true: patients with different diagnoses may share biological features, symptom dimensions, or functional impairments. As a result, the field has repeatedly encountered a difficult translational gap between promising candidate biomarkers and tools that can meaningfully improve diagnosis or treatment selection.

Neuroimaging illustrates the problem. Imaging research has identified abnormalities associated with psychiatric disorders, but an American Psychiatric Association (APA) neuroimaging report found that many imaging abnormalities had relatively small effect sizes, limiting their specificity and sensitivity for individual-level classification.⁵ In other words, a finding may be scientifically meaningful across a study cohort while still falling short as a diagnostic test for a single patient. That distinction is central to the entire psychiatric biomarker field.

Moving beyond this gap will likely require larger and more integrated approaches than many earlier biomarker studies could provide. Effective psychiatric biomarker identification requires large-scale, multicenter, multidimensional data integration that includes psychological, biological, physiological, and behavioral data.4 This reflects the complexity of the disorders themselves. A single marker may rarely capture enough information on its own, especially when symptoms, biology, environment, function, and treatment response interact over time.

The more realistic translational path is therefore not simply to find a standalone test that maps neatly onto an existing diagnosis. It is to define what decision a biomarker is meant to support, then validate it for that purpose. A marker used to enrich a clinical trial may require a different evidentiary standard than one used for diagnosis, prognosis, treatment-response prediction, or pharmacodynamic monitoring. Without that context, even a biologically interesting signal can remain stranded in the research literature rather than becoming a practical tool for psychiatry.

The difficulty of translating psychiatric biomarkers into clinical tools has encouraged a broader shift in how researchers think about mental illness. Rather than beginning only with diagnostic categories and then searching for a biomarker that maps onto each disorder, many research efforts now look for measurable biological and behavioral dimensions that may cut across diagnoses. This is where Research Domain Criteria, or RDoC, becomes useful as a framework for biomarker discovery.

RDoC should be understood as a research scaffold, not as a replacement for clinical diagnosis. The National Institute of Mental Health explicitly states that RDoC is not intended to serve as a diagnostic guide or replace current diagnostic systems.⁶ Its purpose is different: to support research into mental health and illness through fundamental psychological and biological systems, including how dysfunction in those systems may contribute to symptoms. That distinction matters because it prevents the framework from being overstated. RDoC does not solve the diagnostic problem on its own, but it helps researchers ask different kinds of questions.

Instead of asking whether a single biomarker can identify a DSM-defined disorder, an RDoC-informed approach might ask whether a measurable biological system, circuit, behavior, or physiological process is linked to a symptom dimension across multiple conditions. RDoC encourages integration across multiple units of analysis, including behavior, genetics, physiology, and self-report.⁶ It also distinguishes biological units, such as genes, molecules, cells, neural circuits, and physiology from behavior and self-report, which is especially relevant as biomarker language expands to include more digital and behavioral measures.³

This dimensional approach is important because psychiatric symptoms rarely respect diagnostic boundaries. Problems with reward processing, threat response, cognition, arousal, sleep, or social function may appear across different disorders, even if they are organized differently within current clinical categories. RDoC was developed to support research based on measurable behavior and neurobiological measures and to inform future conceptions of mental illness and revisions to diagnostic manuals.⁷ In that sense, it offers a way to connect symptom expression with underlying systems without assuming that every diagnostic category has a single, discrete biological signature.

For biomarker development, the value of RDoC is practical as much as conceptual. It encourages researchers to define the biological or behavioral process they are measuring, clarify how that process relates to symptoms or function, and determine whether the marker has a specific use. That orientation may be better suited to psychiatric drug development and patient stratification than a one-diagnosis, one-biomarker model. It also helps preserve a useful distinction introduced earlier: a clinically meaningful biomarker should be more than a measurable signal. It should be tied to a plausible disease-relevant process and validated for a defined purpose.

The search for psychiatric biomarkers now spans a wide range of biological, physiological, and digitally derived measures. That breadth reflects both the complexity of psychiatric illness and the difficulty of identifying any single marker that can explain, diagnose, or predict the course of a disorder. Across modalities, the most useful question is not simply whether a signal differs between groups, but whether it can support a specific clinical or drug-development decision.

Genetic and molecular approaches have been especially important in challenging the idea that current diagnostic categories map cleanly onto distinct biological entities. Psychiatric disorders display high levels of comorbidity and genetic overlap, complicating traditional diagnostic boundaries. Genomic methods have also shown substantial shared genetic signal between schizophrenia and bipolar disorder, reinforcing the idea that biologic risk may cut across categories that remain separate in clinical practice. In a study of 14 psychiatric disorders published in Nature, analyses identified five underlying genomic factors that explained most genetic variance on average and were associated with 238 pleiotropic loci.⁸ These findings do not turn genetics into a simple diagnostic tool, but they do show why biomarker discovery may need to focus on shared biological architecture, symptom dimensions, and disease-relevant pathways rather than diagnosis alone.

That broader molecular search extends beyond inherited genetic risk. Psychiatric biomarker research has also investigated transcriptomics, proteomics, metabolomics, and epigenetics, each offering a different view of biological activity and regulation.¹ These approaches may eventually help researchers characterize disease subtypes, treatment response, or biological state, but they also add complexity. A molecular signal may vary by diagnosis, disease stage, medication exposure, stress, inflammation, sleep, or other factors. As a result, molecular biomarkers may be most informative when interpreted within a larger clinical and biological context rather than treated as standalone diagnostic answers.

Neuroimaging has provided another major avenue for psychiatric biomarker research. Studies have shown that psychiatric disorders are associated with abnormalities in brain function, structure, and receptor pharmacology. This work has helped deepen scientific understanding of psychiatric illness and has supported the shift toward systems, circuits, and dimensional biology. Yet the clinical translation of neuroimaging remains limited. The APA work group concluded that, despite promising findings, there were no brain-imaging biomarkers clinically useful for any psychiatric diagnostic category by the standards used in that report.5 The same report found that neuroimaging studies had not significantly affected diagnosis or treatment of individual patients.

That gap between discovery and use is important. Neuroimaging can reveal patterns across groups, but clinical diagnosis requires tools that can guide decisions for individual patients with sufficient accuracy and relevance. A scan finding that contributes to research knowledge may still be too nonspecific, too variable, or too dependent on study conditions to function as a routine diagnostic biomarker. This does not diminish the scientific value of neuroimaging. It places that value in the right context: neuroimaging may be especially useful for mechanistic understanding, drug development, and subgroup analysis, even if it has not yet become a routine diagnostic tool for psychiatric practice.

Electroencephalography (EEG) offers a different type of physiological signal, with potential appeal because it measures brain electrical activity more directly and can be more accessible than many imaging approaches. However, EEG-based biomarker development faces its own translational barriers. In major depressive disorder, EEG-based biomarker research lacks a “golden standard” for preprocessing steps, and technical standardization remains a key issue.⁹ That matters because preprocessing choices can influence what signal is extracted, how results are compared across studies, and whether findings can be reproduced.

For EEG to contribute meaningfully to psychiatric biomarker development, the field will need more than promising associations. It will need consistent methods, transparent analytic pipelines, and validation across settings. Without that technical foundation, even biologically plausible EEG signals may remain difficult to compare, interpret, or apply in clinical development and care.

Digital biomarkers add another layer of promise and ambiguity. Digital tools can capture aspects of daily life that traditional clinical visits may miss, including behavior, activity, cognition, social patterns, sleep-related signals, and physiological measures. This could be valuable in psychiatric disorders, where symptoms often fluctuate over time and real-world functioning is central to clinical meaning. At the same time, digital biomarker terminology in psychiatry remains unsettled. Some measures labeled as digital biomarkers include self-report, social, behavioral, cognitive, and physiological indicators, which can blur the meaning of the term.³

That ambiguity matters because digital measurement is not automatically biomarker measurement. A digital tool may provide a useful clinical measure, functional assessment, patient-reported outcome, behavioral signal, or monitoring endpoint without necessarily qualifying as a biomarker. The “bio-” component becomes unclear when the term is applied too broadly. One proposed approach is to reserve “digital biomarker” for biological parameters with a plausible pathway connecting them to the condition of interest. That kind of discipline would help preserve the value of digital tools while preventing the biomarker label from becoming so broad that it loses scientific and regulatory meaning.

Because psychiatric biomarkers are often discussed in relation to diagnosis, it is easy to imagine the goal as a future blood test, scan, or digital readout that can identify a disorder with confidence. That may be an important long-term aspiration, but the nearer-term opportunity may be more practical: using biomarkers to make psychiatric drug development more biologically informed, more selective, and more capable of detecting meaningful treatment effects.

This distinction matters because drug development does not always require a biomarker to function as a diagnostic test. A biomarker may be valuable if it helps identify a biologically relevant subgroup, confirms that a therapy is engaging its intended target, supports dose selection, or helps determine whether a treatment is affecting the pathway it was designed to modulate. In psychiatry, where diagnostic categories can include biologically diverse patient populations, those uses may be especially important.

Schizophrenia and psychosis-spectrum drug development provide a useful example. A 2024 review found that no validated and qualified neuroimaging biomarkers were available to support the development of new therapeutics in schizophrenia, underscoring how far the field remains from routine regulatory-grade biomarker use.¹⁰ At the same time, neuroimaging can still support target discovery, target engagement, and dose selection in schizophrenia and psychosis-spectrum drug development. That difference is critical. A tool may not yet be ready to guide clinical diagnosis or support a qualified biomarker claim, but it can still help developers understand whether a therapeutic hypothesis is biologically plausible and whether a candidate is behaving as expected.

Response and predictive neuroimaging biomarkers are also being evaluated in patient populations, although they continue to play a limited role. This reflects a broader reality across psychiatric biomarker research: the strongest near-term value may come from defined, decision-specific applications rather than broad clinical claims. A biomarker that helps select a more appropriate study population or interpret early pharmacodynamic activity could be useful even if it cannot diagnose a disorder on its own.

That approach aligns with recommendations to focus neuropsychiatric biomarker development on discrete biological dysfunctions and/or symptom domains rather than diagnoses.¹¹ For drug developers, this can be a more actionable framework. Instead of treating a diagnostic label as the primary biological unit, a development program can ask whether a therapy is intended to affect a specific pathway, circuit, symptom domain, or functional impairment, then identify biomarkers that help test that relationship.

Biomarker-based patient stratification may be especially relevant in phase II and phase III trials, where heterogeneous enrollment can make it harder to detect a true treatment effect. A 2024 pragmatic guide advocates biomarker-based stratification in these later-stage trials to increase sensitivity and power and reduce costs.¹¹ In practice, this could mean using biomarkers to enrich for patients more likely to show a relevant biological dysfunction, respond to a mechanism of action, or experience a measurable outcome within the trial design.

This is where psychiatric biomarkers may have their first major impact. Rather than replacing clinical diagnosis, they may help developers design better studies around it. They could support more precise inclusion criteria, more informative early-phase decisions, stronger evidence of target engagement, and clearer interpretation of heterogeneous outcomes. For a field in which many disorders are still defined by symptoms but therapies increasingly aim at specific biological mechanisms, that role could be transformative even before biomarkers become routine clinical diagnostic tools.

A promising research signal is not the same thing as a qualified biomarker. This distinction is especially important in psychiatry, where many candidate signals may be biologically interesting but not yet ready to guide development decisions, support regulatory claims, or shape clinical practice. The key question is not simply whether a biomarker correlates with a disorder, symptom domain, or treatment response. The key question is whether it is reliable, interpretable, and fit for a defined purpose.

The FDA’s Biomarker Qualification Program provides a useful way to think about that standard. The program works with stakeholders to develop biomarkers as drug development tools, and FDA qualifies biomarkers for specific contexts of use that address specified drug development needs.¹² That context-of-use framing is central. A biomarker does not become useful in the abstract; it becomes useful when it can support a particular decision in a particular setting.

For psychiatric drug development, that could mean several different things. A biomarker might help identify patients with a relevant biological feature, confirm that a therapy is engaging a target, support dose selection, stratify trial participants, enrich a study population, or provide pharmacodynamic evidence that a pathway is being modulated. Each application requires evidence matched to the intended use. A marker used for exploratory subgroup analysis does not need to meet the same evidentiary standard as one used to select patients for a pivotal trial or support a regulatory decision.

This is where enrichment strategies become especially relevant. FDA guidance describes enrichment approaches that can reduce heterogeneity by carefully defining entry criteria and ensuring enrolled patients have the disease of interest.¹³ For psychiatry, reducing heterogeneity is not a minor operational issue; it is one of the central challenges in trial design. When diagnostic categories include patients with different biological drivers, symptom profiles, comorbidities, and treatment histories, a trial may struggle to detect a signal even if a therapy benefits a subset of participants.

The FDA also describes prognostic enrichment as enrolling patients with baseline features associated with a higher likelihood of events of interest. In psychiatric development, that principle could be relevant when sponsors need to identify participants more likely to worsen, relapse, respond, or demonstrate measurable change within the timeframe of a study. The biomarker’s value would not come from replacing diagnosis, but from improving the study’s ability to answer a specific question.

The validation gap is therefore both scientific and practical. Candidate biomarkers must move from exploratory association to reproducible measurement, then to evidence that the marker improves a defined decision. For psychiatric disorders, that path is complicated by heterogeneity, overlapping symptoms, variable disease course, and the challenge of connecting biological signals to clinical outcomes. Regulatory-grade biomarker development will require disciplined definitions, standardized assays or measurement methods, multicenter validation, and clarity about how the biomarker will be used.

That discipline may also help the field avoid overclaiming. A biomarker does not need to solve all of psychiatry to be valuable. It needs to solve a specific problem better than the tools currently available. In the near term, that problem may be trial enrichment, target engagement, patient stratification, or response prediction rather than standalone diagnosis. Framed this way, psychiatric biomarkers can advance through a more realistic translational pathway: not as universal answers, but as validated tools built for defined decisions.

The future of psychiatric biomarkers is unlikely to depend on a single universal test for depression, schizophrenia, bipolar disorder, or any other complex psychiatric condition. The literature points toward a more layered model, in which biological, physiological, behavioral, digital, and clinical measures are combined and validated for specific uses. That model is less dramatic than the idea of replacing symptom-based diagnosis with a single objective readout, but it is also more credible.

Psychiatry still lacks robust, reliable, and valid biomarkers that can support objective diagnosis and individualized treatment recommendations. That gap remains central to the field. However, the difficulty is not simply that researchers have failed to find measurable biological signals. Diagnostic biomarkers for mental disorders remain challenging because psychiatric conditions are heterogeneous and symptoms often overlap across disorders. A biomarker that performs well in one narrowly defined study population may not generalize across different clinical settings, comorbidities, disease stages, or treatment histories.

That reality argues for a shift in expectations. Rather than searching only for biomarkers that map neatly onto existing diagnoses, the field may need to build toolkits around defined biological dysfunctions, symptom domains, and development decisions. This is already reflected in neuropsychiatric drug development, where biomarker development may be most productive when focused on biological dysfunction and symptom domains rather than diagnoses. Such an approach aligns more closely with how psychiatric illness often presents: not as cleanly separated biological entities, but as overlapping patterns of symptoms, function, physiology, and risk.

Effective biomarker identification will likely require large-scale, multicenter, multidimensional data integration. In practice, this means that psychiatric biomarkers may need to be interpreted alongside clinical assessments, behavioral data, physiological measures, molecular profiles, imaging findings, digital signals, and treatment-response patterns. No single layer is likely to carry the full burden of diagnosis or prediction. The value may come from the way multiple layers converge to clarify patient subgroups, disease mechanisms, treatment selection, or trial design.

For pharma and biotech developers, this layered model may be especially important. Biomarkers could help make psychiatric drug development less dependent on broad diagnostic labels alone and more attentive to mechanism, target engagement, patient stratification, and measurable change. For clinicians, the long-term opportunity is more individualized care, but only if candidate tools are validated rigorously and used within clear clinical contexts. For patients, the promise is not merely a more objective label, but a better path toward understanding which intervention is most likely to help.

The most responsible future-facing view is therefore neither skepticism nor hype. Psychiatric biomarkers are not ready to replace clinical diagnosis, and many candidate markers will not survive the demands of validation. But the field is moving toward a more objective and biologically informed psychiatry, built not around one decisive test but around a set of tools that can answer specific questions. The closer those tools are tied to defined mechanisms, symptom domains, and contexts of use, the more likely they are to improve research, drug development, and eventually patient care.

1. García-Gutiérrez, Maria Salud, et al. “Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality.” Front. Psychiatry. Sec. Molecular Psychiatry. 11: 00432 (2020).

2. Abi-Dargham, Anissa, et al. “Candidate biomarkers in psychiatric disorders: state of the field.” World Psychiatry. 22: 236–262 (2023).

3. Mulinari, Shai. “Aligning digital biomarker definitions in psychiatry with the National Institute of Mental Health Research Domain Criteria framework.” NPP–Digital Psychiatry and Neuroscience. 2: 15 (2024).

4. Liu, Jin, Haoting Wang, and Lingjiang Li. “Rethinking the studies of diagnostic biomarkers for mental disorders.” Meta-Radiology. 3: 100135 (2025).

5. First, Michael, et al. “Consensus Report of the APA Work Group on Neuroimaging Markers of Psychiatric Disorders: Resource Document.” American Psychiatric Association. Jul. 2012.

6. “About RDoC.” National Institute of Mental Health. Accessed 11 May 2026.

7. Cuthbert, Bruce N. “Research Domain Criteria (RDoC): Progress and Potential.” Current Directions in Psychological Science. 1 Mar. 2022.

8. Grotzinger, Andrew D, et al. “Mapping the genetic landscape across 14 psychiatric disorders.” Nature. 649: 406–415 (2026).

9. Simmatis, Leif, et al. “Technical and clinical considerations for electroencephalography-based biomarkers for major depressive disorder.” npj Mental Health Research. 2: 18 (2023).

10. Preller, Katrin H, et al. “Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia.” Biological Psychiatry. 96: 666–672 (2024).

11. Umbricht, Daniel, Martien JH Kas, and Gerard R Dawson. “The role of biomarkers in clinical development of drugs for neuropsychiatric disorders - A pragmatic guide.” European Neuropsychopharmacology. 88: 66–77 (2024).

12. “Biomarker Qualification Program.” U.S. Food and Drug Administration. 16 May 2025.

13. Zineh, Issam. “Use of Enrichment in Drug Development Trial Design.” U.S. Food and Drug Administration. 8 Sep. 2017.